A number of firms have modified their ratings and price targets on shares of Globus Medical (NYSE: GMED) recently:

  • 10/19/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/19/2017 – Globus Medical had its price target lowered by analysts at Barclays PLC from $28.00 to $27.00. They now have an “underweight” rating on the stock.
  • 10/19/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 10/13/2017 – Globus Medical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/7/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/4/2017 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 9/26/2017 – Globus Medical is now covered by analysts at Needham & Company LLC. They set a “hold” rating on the stock. They wrote, “GMED’s core spine organic growth has slowed though we expect some improvement in 2018 due to sales force enhancements. Its Emerging Technologies business should begin to add to growth in 2018 as well. But even accounting for this, we’re concerned that consensus 2018 estimates may be too high. And we believe that GMED’s earnings growth is going to be mostly driven by revenue growth.””
  • 9/22/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $38.00 price target on the stock.
  • 9/18/2017 – Globus Medical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/14/2017 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 9/7/2017 – Globus Medical is now covered by analysts at BTIG Research. They set a “buy” rating and a $37.00 price target on the stock.
  • 9/7/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/4/2017 – Globus Medical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “

Globus Medical (NYSE:GMED) last posted its earnings results on Wednesday, August 2nd. The medical device company reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.02. The business had revenue of $152.39 million during the quarter, compared to analyst estimates of $150.94 million. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.29 EPS.

In other Globus Medical news, insider A Brett Murphy sold 15,000 shares of Globus Medical stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $29.99, for a total value of $449,850.00. Following the completion of the sale, the insider now owns 101,217 shares of the company’s stock, valued at approximately $3,035,497.83. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 28.21% of the stock is currently owned by company insiders.

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.